March 8, 2021 -- Contract development and manufacturing organization (CDMO) Cytovance Biologics is offering a new licensing opportunity for gene therapy plasmid DNA (pDNA) manufacturing.
The company's Keystone Expression System pDNA platform is an end-to-end solution for manufacturing good manufacturing practice (GMP) pDNA at scale in a manufacturer's own facility. The platform is designed to process plasmids with low-shear lysis and purification steps. The system can reduce the time and cost of producing pDNA-based products, according to the company.
License opportunities are currently available for either 30- or 300-L manufacturing scales. Each license includes end-to-end documentation including process descriptions, analytical standard operating procedures, critical equipment lists, and facility layout. Cytovance is also offering hands-on process training at manufacturing facilities.
Copyright © 2021 scienceboard.net